Skip to content
Head to head

Generate Biomedicines vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: GENB · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

GENB -24.6%VRTX +3.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
GENBVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price9.54515.02
Change today-8.00%-1.08%
1-year return--+22.0%
Market cap$1.23B$130.58B
52-week range9.40 – 22.67412.27 – 568.67
Valuation
P/E (TTM)-5.0333.14
P/E percentile, own 5-yr range69th99th
P/B3.236.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.9615.32
Net profit (TTM)$-252.77M$3.88B
Revenue (TTM)$21.07M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-56.2%+11.8%
Gross margin--85.5%
Operating margin-1382.0%33.1%
Net margin-1381.8%30.7%
Free cash flow (TTM)$-252.69M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership83.2%96.8%
Insider activity (12mo)19 buy / 3 sell28 buy / 22 sell
Short interest (% of float)7.1%1.9%
Analyst consensus100% buy (3)95% buy / 5% hold (21)
Analyst price target$26 (+173%)$624 (+21%)
StockVane view
StockVane Quant RatingC (0)C (68)
Company
Employees3126,400
Founded20181989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.